Left ventricular hypertrophy--the problem and possible solutions

Area of Science:

• Cardiology
• Hypertension Research
• Cardiovascular Disease

Background:

• Left ventricular hypertrophy (LVH) signifies pathological cardiac structural changes.
• LVH is a potent, reversible predictor of cardiovascular risk, with a continuous relationship between left ventricular mass (LVM) and cardiovascular events.
• A strong correlation exists between LVH and blood pressure, though the mechanism by which increased cardiac workload promotes cardiovascular disease requires further elucidation.

Purpose of the Study:

• To explore the relationship between blood pressure variability and LVH.
• To investigate the role of the renin angiotensin-aldosterone system (RAAS) in LVH and target-organ damage.
• To evaluate the potential benefits of RAAS-targeting agents, particularly angiotensin II receptor blockers (ARBs), in managing LVH and cardiovascular risk.

Main Methods:

• Analysis of the correlation between ambulatory and resting blood pressure measurements with LVH.
• Examination of the association between blood pressure variation, specifically the early morning rise, and increased LVM.
• Review of the pathological role of angiotensin II and the efficacy of RAAS-inhibiting agents in LVH regression.

Main Results:

• Ambulatory blood pressure measurements correlate more strongly with LVH than resting blood pressure.
• An early morning rise in blood pressure is significantly associated with increased LVM.
• Antihypertensive agents, particularly those targeting the RAAS, can induce LVH regression.

Conclusions:

• LVH is a critical, modifiable risk factor for cardiovascular events.
• Agents targeting the RAAS, such as ARBs, offer a promising therapeutic strategy for LVH management due to their tolerability and potential for complete RAAS blockade.
• Pharmacological differences among ARBs may influence their cardioprotective effects beyond blood pressure reduction.